Basic Information
| LncRNA/CircRNA Name | SNHG7 |
| Synonyms | NA |
| Region | GRCh38_9:136721366-136728184 |
| Ensemble | ENSG00000233016 |
| Refseq | NR_003672 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, in vitro knockdown, etc. |
| Sample | NSCLC tissues, cisplatin-resistant A549/DDP cell line |
| Expression Pattern | up-regulated |
| Function Description | Compared with adjacent normal tissues, SNHG7 was highly expressed in NSCLC tissues. Moreover, SNHG7 expression was significantly higher in advanced-stage NSCLC patients than those in early-stage. SNHG7 level remained significantly higher in DDP-resistant NSCLC tissues and cell lines as well. Knockdown of SNHG7 remarkably enhanced cisplatin-resistance in NSCLC cells, manifesting as decreased cell viability, migratory and invasive rates, DNA synthesis capacity, and promoted apoptosis. Meanwhile, SNHG7 knockdown down-regulated the mRNA levels of matrix metalloprotein2 (MMP2), MMP7 and MMP9 in vitro. After SNHG7 knockdown, the expressions of drug-resistant and relative genes in the PI3K/AKT pathway were notably down-regulated. CONCLUSIONS: SNHG7 induces the development of cisplatin-resistance in NSCLC through upregulating MRD1 and BCRP via PI3K/AKT pathway. |
| Pubmed ID | 31486493 |
| Year | 2019 |
| Title | SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway |
External Links
| Links for SNHG7 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |